antisense oligo
TRANSCRIPT
-
7/30/2019 Antisense Oligo
1/40
Antisense Oligonucleotide
-
7/30/2019 Antisense Oligo
2/40
The term antisense oligonucleotides refers tomolecules made of synthetic genetic material,
which interact with natural genetic material(DNA or RNA) harboring the information forproduction of proteins.
What is antisense oligonucleotides?
-
7/30/2019 Antisense Oligo
3/40
Antisense Oligonucleotides are unmodified or chemicallymodified ssDNA, RNA or their analogs. They are 13-25nucleotides long and are specifically designed to hybridizeto the corresponding RNA by Watson-Crick binding
Initially, cellular nucleases dramatically reduce the
effectiveness of antisense oligonucleotides by rapidlydegrading these molecules after administration.
These obstacles can be overcome in applications
utilizing synthetic oligonucleotides by altering the
nature of the phosphodiester bond by replacing an
oxygen with sulfur. Such modified oligonucleotides
are termed phosphorothionates.
-
7/30/2019 Antisense Oligo
4/40
Antisense Technology
Antisense refers to short DNA or RNA sequences, termed
oligonucleotides, which are designed to be complementary to aspecific gene sequence. The goal is to alter specific gene expression
resulting from the binding of the antisense oligonucleotide to a
unique gene sequence.
Antisense technology was first effectively used in plants to alter the
levels of various degradative enzymes or plant pigments.
-
7/30/2019 Antisense Oligo
5/40
To prevent protein production from a targeted gene.
The exact mechanism by which this occurs remains uncertain.
Proposed mechanisms include
Triplex formation,
Blocking RNA splicing,
Preventing transport of the mRNA antisense complex into the
cytoplasm,
Increasing RNA degradation, or blocking the initiation of
translation.
Principle of antisense technology
-
7/30/2019 Antisense Oligo
6/40
-
7/30/2019 Antisense Oligo
7/40
Antisense RNA can be generated by reversing the orientation of a gene withrespect to its promoter, and can anneal with the wild-type transcript to formduplex RNA.
-
7/30/2019 Antisense Oligo
8/40
-
7/30/2019 Antisense Oligo
9/40
Anti-mRNA Strategies
-
7/30/2019 Antisense Oligo
10/40
A regulator RNA functions by forming a duplex region with a target RNA.
The duplex may block initiation of translation, cause termination of transcription, or
create a target for an endonuclease.
Small RNA molecules can regulate translation
-
7/30/2019 Antisense Oligo
11/40
Bacteria contain regulator RNAs
Bacterial regulator RNAs are called sRNAs.
Several of the sRNAs are bound by the protein Hfq, which increasestheir effectiveness.
E. coli contains at least 17 different sRNAs. Some of the sRNAs are
general regulators that affect many target genes.
-
7/30/2019 Antisense Oligo
12/40
MicroRNAs are regulators in many eukaryotes
Animal and plant genomes code for many short (-22 base) RNA molecules, called
microRNAs.
MicroRNAs regulate gene expression by base pairing with complementary
sequences in target mRNAs.
Very small RNAs are gene regulators in many eukaryotes. The first example was
discovered in the nematode C. elegans as the result of the interaction between theregulator gene lin4 and its target gene, linl4.
-
7/30/2019 Antisense Oligo
13/40
The lin14 target gene regulates larval
development. Expression of Iinl4 is controlled
by lin4, which codes for a small transcript of22 nucleotides. The lin4 transcripts are
complementary to a 10-base sequence that is
repeated 7 times in the 3' non translated region
of lin14. Expression of lin4 represses
expression of lin14 post-transcriptionally, most
likely because the base pairing reactionbetween the two RNAs leads to degradation of
the mRNA. This system is especially
interesting in implicating the 3' end as a site for
regulation.
-
7/30/2019 Antisense Oligo
14/40
RNA interference is related to gene silencing
dsRNA is degraded by ATP-dependent cleavage to give oligonucleotides of
21-23 bases. The short RNA is sometimes called siRNA (short interfering
RNA). Figure shows that the mechanism of cleavage involves making breaks
relative to each 3' end of a long dsRNA to generate siRNA fragments with
short (2 base) protruding 3' ends. The same enzyme (Dicer) that generates
micro-RNAs is responsible for the cleavage.
-
7/30/2019 Antisense Oligo
15/40
How Does it Work? (or)
How does the double stranded RNA cause gene suppression?
Dicer Recognizes the double stranded RNA and chops it up into small
fragments between 21-25 base pairs in length.
These short RNA fragments (called small interfering RNA, or siRNA) bind to
the RNA-induced silencing complex (RISC).
The RISC is activated when the siRNA unwinds and the activated complex
binds to the corresponding mRNA using the antisense RNA.
The RISC contains an enzyme to cleave the bound mRNA (called Slicer in
Drosophila) and therefore cause gene suppression.
Once the mRNA has been cleaved, it can no longer be translated into
functional protein
http://www.nature.com/nrg/journal/v2/n2/anim
ation/nrg0201_110a_swf_MEDIA1.html
http://www.nature.com/nrg/journal/v2/n2/animation/nrg0201_110a_swf_MEDIA1.htmlhttp://www.nature.com/nrg/journal/v2/n2/animation/nrg0201_110a_swf_MEDIA1.htmlhttp://www.nature.com/nrg/journal/v2/n2/animation/nrg0201_110a_swf_MEDIA1.htmlhttp://www.nature.com/nrg/journal/v2/n2/animation/nrg0201_110a_swf_MEDIA1.html -
7/30/2019 Antisense Oligo
16/40
Mechanism of action of RNAi.
Double stranded RNA is
introduced into a cell and getschopped up by the enzyme dicer to
form siRNA. siRNA then binds to
the RISC complex and is
unwound. The anitsense RNA
complexed with RISC binds to its
corresponding mRNA which is thecleaved by the enzyme slicer
rendering it inactive.
-
7/30/2019 Antisense Oligo
17/40
Mechanism of Action of Antisense Oligonucleotides.
RNA Interference (RNAi)
RNAi is an innate
cellular process thatdirects the degradationof mRNA homologous toshort double strandedRNA (dsRNA),
-
7/30/2019 Antisense Oligo
18/40
Mechanism of Action of Antisense Oligonucleotides.
RNA Interference (RNAi)
-
7/30/2019 Antisense Oligo
19/40
RNAi occurs post-transcriptionally
when an siRNA induces degradation of
a complementary mRNA. Figure 11.39
suggests that the siRNA may provide a
template that directs a nuclease todegrade mRNAs that are
complementary to one or both strands,
perhaps by a process in which the
mRNA pairs with the fragments. It is
likely that a helicase is required to
assist the pairing reaction. The siRNAdirects cleavage of the mRNA in the
middle of the paired segment. These
reactions occur within a
ribonucleoprotein complex called RISC
(RNA-induced silencing complex).
-
7/30/2019 Antisense Oligo
20/40
RNA interference (RNAi) can functionally inactivate genes in
C. elegans and some other organisms
-
7/30/2019 Antisense Oligo
21/40
(a) Production of double-stranded RNA
(dsRNA) for RNAi of a specific target gene. The coding sequence of the gene, derived from
either a cDNA clone or a segment of genomic DNA, is placed in two orientations in a
plasmid vector adjacent to a strong promoter. Transcription of both constructs in vitrousing RNA polymerase and ribonucleotide triphosphates yields many RNA copies in the
sense orientation (identical with the mRNA sequence) or complementary antisense
orientation. Under suitable conditions, these complementary RNA molecules will
hybridize to form dsRNA.
(b) Inhibition ofmex3 RNA expression in worm embryos by RNAi.
(Left) Expression of mex3 RNA in embryos was assayed by in situ hybridization with a
fluorescently labeled probe (purple) specific for this mRNA.
(Right) The embryo derived from a worm injected with double-stranded mex3 mRNA
produces little or no endogenous mex3 mRNA, as indicated by the absence of color. Each
four-cell stage embryo is 50 m in length.
Mex3 Regulate blastomere
-
7/30/2019 Antisense Oligo
22/40
Double-Stranded RNA Molecules Can Interfere with Gene Function by Targeting mRNA
for Destruction
Researchers are exploiting a recently discovered phenomenon known as RNA
interference (RNAi) to inhibit the function of specific genes. This approach is
technically simpler than the methods described above for disrupting genes. First
observed in the roundworm C. elegans, RNAi refers to the ability of a double-stranded
(ds) RNA to block expression of its corresponding single-stranded mRNA but not that
of mRNAs with a different sequence.
To use RNAi for intentional silencing of a gene of interest, investigators first produce
dsRNA based on the sequence of the gene to be inactivated (Figure 9-43a). ThisdsRNA is injected into the gonad of an adult worm, where it has access to the
developing embryos. As the embryos develop, the mRNA molecules corresponding to
the injected dsRNA are rapidly destroyed. The resulting worms display a phenotype
similar to the one that would result from disruption of the corresponding gene itself.
In some cases, entry of just a few molecules of a particular dsRNA into a cell is
sufficient to inactivate many copies of the corresponding mRNA. Figure 9-43billustrates the ability of an injected dsRNA to interfere with production of the
corresponding endogenous mRNA in C. elegans embryos. In this experiment, the
mRNA levels in embryos were determined by incubating the embryos with a
fluorescently labeled probe specific for the mRNA of interest.
This technique, in situ hybridization, is useful in assaying expression of a particular
mRNA in cells and tissue sections.
-
7/30/2019 Antisense Oligo
23/40
Mechanism of Action of Antisense Oligonucleotides.
Translational Arrest by Blocking the Ribosome.
Th d RNA ti t th PKR hi h i ti t th t l ti i iti ti f t IF2
-
7/30/2019 Antisense Oligo
24/40
The dsRNA activates the enzyme PKR, which inactivates the translation initiation factor eIF2a
by phosphorylating it. And it activates 2'5' oligoadenylate synthetase, whose product activates
RNAase L, which degrades all mRNAs. However, it turns out that these reactions require dsRNA
that is longer than 26 nucleotides. If shorter dsRNA (21-23 nucleotides) is introduced into
mammalian cells, it triggers the specific degradation of complementary RNAs just as with the
RNAi technique in worms and flies. With this advance, it seems likely that RNAi will become the
universal mechanism of choice for turning off the expression of a specific gene.
-
7/30/2019 Antisense Oligo
25/40
Activation of RNase H
Mechanism of Action of Antisense Oligonucleotides.
-
7/30/2019 Antisense Oligo
26/40
Mechanism of Action of Antisense Oligonucleotides.
Ribozymes
Ribozymes are RNA molecules
that catalyze biochemical reactions.
Ribozymes cleave single-stranded regions in RNAthrough transesterification orhydrolysis reactions that resultin cleavage of phosphordiesterbonds
-
7/30/2019 Antisense Oligo
27/40
A specifically-designed ribozyme cleaves a specific pathogenic RNAmolecule to make it inactive. For example, the viral RNA causing
hepatitis C.
Very promising results using cell cultures.
The ribozyme is synthesized in vitro and administrated to the
patient.
Problems: half-life too short and low potency once in the body.
Ribozymes
-
7/30/2019 Antisense Oligo
28/40
Endocytosis
Micro injectionLiposome encapsulation
Electroporation
Delivery of antisense oligonucleotides into target cells or
the cell nucleus has been problematic. The variety of
viral and non-viral delivery systems previously discussed
are currently being explored to overcome this obstacle.
-
7/30/2019 Antisense Oligo
29/40
The first generation of vectors developed were liposomes, which are vesicular colloid
vesicles generally composed of bilayers of phospholipids and cholesterol. Liposomes
can be neutral or cationic, depending on the nature of the phospholipids. The nucleic
acid can be easily encapsulated in the liposome interior, which contains an aqueous
compartment, or be bound to the liposome surface by electrostatic interactions. These
vectors, because of their positive charge, have high affinity for cell membranes, which
are negatively charged under physiological conditions. As these vectors use the
endosomal pathway to deliver oligonucleotides into cells, certain helper molecules
have been added into the liposomes to allow the oligonucleotides to escape from the
endosomes; these include species such as chloroquine and 1,2-dioleoyl-sn-glycero-3-
phosphatidylethanolamine. These helper molecules ultimately induce endosomal
membrane destabilization, allowing leakage of the oligonucleotide, which then appearsto be actively transported in high concentration to the nucleus (8286). Many
commercial vectors, such as Lipofectin and compounds known collectively as
Eufectins, Cytofectin, Lipofectamine, etc., are commonly used in laboratory research
studies. With some of these delivery vehicles, and under defined conditions,
oligonucleotide concentrations of 50 nM may be successfully used.
-
7/30/2019 Antisense Oligo
30/40
A variegated petunia. Upon injection of the gene responsible for purple colouring
in petunias, the flowers became variegated or white rather than deeper purple as
was expected.
Co-Suppression
-
7/30/2019 Antisense Oligo
31/40
Co-Suppression
The first discovery of this inhibition in plants was more than a decade ago and occurred in
petunias. Researchers were trying to deepen the purple colour of the flowers by injecting the
gene responsible into the petunias but were surprised at the result. Instead of a darker flower,
the petunias were either variegated (Figure 2) or completely white! This phenomenon was
termed co-suppression, since both the expression of the existing gene (the initial purple colour),
and the introduced gene (to deepen the purple) were suppressed. Co-suppression has since been
found in many other plant species and also in fungi. It is now known that double stranded RNA is
responsible for this effect.
aRNA and RNAi
When antisense RNA (aRNA) is introduced into a cell, it binds to the already present sense RNA to
inhibit gene expression. So what would happen if sense RNA is prepared and introduced into thecell? Since two strands of sense RNA do not bind to each other, it is logical to think that nothing
would happen with additional sense RNA, but in fact, the opposite happens! The new sense RNA
suppresses gene expression, similar to aRNA. While this may seem like a contradiction, it can be
easily resolved by further examination. The cause is rooted in the prepared sense RNA. It turns out
that preparations of sense RNA actually contain contaminating strands of antisense RNA. The sense
and antisense strands bind to each other, forming a helix. This double helix is the actual suppressor
of its corresponding gene. The suppression of a gene by its corresponding double stranded RNA is
called RNA interference (RNAi), or post-transcriptional gene silencing (PTGS). The gene suppression
by aRNA is likely also due to the formation of an RNA double helix, in this case formed by the sense
RNA of the cell and the introduced antisense RNA.
-
7/30/2019 Antisense Oligo
32/40
The tomato first commercially grown genetically engineered foodto be granted a license for human consumption.
Calgene
Californian company - submitted to the U.S. (FDA) in 1992.
In 1994, the FDA completed its evaluation of the FLAVR SAVR tomato
Flavr Savr Tomato for delay the ripening
Polygalacturonase (PG)
-
7/30/2019 Antisense Oligo
33/40
Antisense RNA methods have also been used for commercial food production.
You may have heard of the Flavr Savr tomato. This tomato was developed by
Calgene Inc. of Davis, California in 1991 and was approved by the U.S. FDA in1994. The tomato was the first whole food created by biotechnology that was
evaluated by the FDA. One of the problems associated with tomato farming is
that the fruit must be picked while still green in order to be shipped to market
without being crushed. The enzyme that causes softening in tomatoes is
polygalacturonase (PG). This enzyme breaks down pectin as the tomato ripens,
leading to a softer fruit. Calgene suppressed the expression of the gene encodingPG by introducing a gene encoding the antisense strand of the mRNA. When
the introduced gene was expressed, the antisense strand bound to the PG
mRNA, suppressing the translation of the enzyme. The Flavr Savr tomatoes
therefore had low PG levels and remained firmer when ripe. This meant the
Flavr Savr tomatoes can ripen on the vine and then be shipped to market.
Although the Flavr Savr tomatoes were approved for sale in the U.S.,production problems and consumer wariness stopped the production of this fruit
in 1997.
-
7/30/2019 Antisense Oligo
34/40
Fel d1 is a small protein made from the skin and salivary glands of cats.
It is so small that it can stay in the air for months. Fel d1 is responsible
for humans allergy to cats.
10% of Americans are allergic to cats (eyes, nose, throat, lungs and skin
are affected). Fed 1d has been inactivated through RNAi, by making
transgenic cats that express thefel d1 dsRNA.
Thefel d1 (RNAi) cats are available from 2007. Price: $3500 (announcedin 2004), today: $5950
Delay for delivery : 24 months minimum or 12 months ($7900).
Orders to Switzerland are possible ($8950 / $10900).
The cats are neutered or spayed to avoid the transgene to be transmitted
to naturally born cats.
-
7/30/2019 Antisense Oligo
35/40
Application of Antisense Oligonucleotides
1.Functional Genomics and Target Validation:
Antisense oligonucleotides can be used to
selectively manipulate the expression of chosengene or genes. The process results in :
A pharmacophore with a well-understoodmechanism of action.
Well characterized distribution and a safe sideeffect profile which could be used as a humantherapeutic.
-
7/30/2019 Antisense Oligo
36/40
2. Potential Therapeutic Applications of AntisenseOligonucleotides
Application of Antisense Oligonucleotides
A wide variety of potential therapeutic applications of
antisense oligonucleotides has been reported in the lastfew years. Major areas of these therapeutic applications include:
2.1.Antiviral
2.2. Antibacterial
2.3. CNS Therapeutics: Antisense Oligonucleotideswill address unmet medical needs for CNSdiseases.
-
7/30/2019 Antisense Oligo
37/40
2. Potential Therapeutic Applications ofAntisense Oligonucleotides
2.4.Inflammation Therapeutics:e.g.Colitis, Lupus, Lunginflammation, Skin inflammation, Transplantationrejection, Reperfusion injury, Rheumatoid Arthritis and
Ocular disease.2.5. Cardiovascular Therapeutics: e.g. prevention of
restenosis, myocardial infarction, rejection inheart transplantation, hypertension andatherosclerosis.
2.6.Regulation of Apoptosis: which will address treatmentof cancer, psoriasis,fibrosis, atherosclerosis, restenosisand others
-
7/30/2019 Antisense Oligo
38/40
2.7. Anticancer:
2. Potential Therapeutic Applications ofAntisense Oligonucleotides
2.8.Other Therapeutic Applications potentials:
diabetes, pain and analgesia, psoriasis, myastheniagravis, hair lossetc
The most recent antisense application as therapeutictool is aimed to treat the SARS and bird Flu
An approved antisense drug
-
7/30/2019 Antisense Oligo
39/40
An approved antisense drug
Vitravene (Isis Pharmaceuticals).
Treatment: cytomegalovirus infections in the eye for patients with HIV.
Vitravene is actually a DNA antisense drug but it is unclear
whether it works by an antisense mechanism.
Under review : Genasense.
Treatment: targets the Bcl-2 protein which is highly expressed in cancer cells.
It is believed that Bcl-2 protects cancer cells from chemotherapy.
So far, promising results in the treatment of malignant melanoma.
Approval by Food and Drug Administration (FDA, USA)
-
7/30/2019 Antisense Oligo
40/40
The clinical experience to date should beconsidered part of the beginning of the story ofantisense treatment, with more clinical trials ofnew antisense drugs soonexpected. Currently over 30 pharmaceutical andbiotechnology companies have declared aninterest in or have an active drug development
program already under way in antisense-basedtherapeuticsThe fuller story, yet to be written, promises tobe rich.
Future of Antisense-Based Biotechnology
The promise of antisense-basedbiotechnology is therefore stronger
than ever.